e-learning
resources
Virtual 2021
05.09.2021
Developments in biomarkers and treatment strategies for chronic lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Improved assay for the quantification of hydroyproline (collagen) in animal models of Idiopathic Pulmonary Fibrosis.
M. Mcelroy (Edinburgh (Edinburgh), United Kingdom), J. Davis (Edinburgh (Edinburgh), United Kingdom), A. Marsden (Edinburgh (Edinburgh), United Kingdom), P. Filis (Edinburgh (Edinburgh), United Kingdom), D. Spark (Edinburgh (Edinburgh), United Kingdom), I. Love (Edinburgh (Edinburgh), United Kingdom)
Source:
Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases
Session:
Developments in biomarkers and treatment strategies for chronic lung diseases
Session type:
E-poster
Number:
729
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Mcelroy (Edinburgh (Edinburgh), United Kingdom), J. Davis (Edinburgh (Edinburgh), United Kingdom), A. Marsden (Edinburgh (Edinburgh), United Kingdom), P. Filis (Edinburgh (Edinburgh), United Kingdom), D. Spark (Edinburgh (Edinburgh), United Kingdom), I. Love (Edinburgh (Edinburgh), United Kingdom). Improved assay for the quantification of hydroyproline (collagen) in animal models of Idiopathic Pulmonary Fibrosis.. 729
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Metabolic shift during TGF- β-induced collagen synthesis
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Pulmonary fibroblasts are affected by notch ligands in vitro
Source: International Congress 2015 – Airway remodelling: recent developments
Year: 2015
Evaluation of Idiopathic Pulmonary Fibrosis therapies, Pirfenidone and Nintedanib, in a Human Experimental Model of Fibrosis
Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2019
Pulmonary distribution and localization of pirfenidone in animal models of IPF by MS/MS
Source: International Congress 2014 – ILDs 4
Year: 2014
LATE-BREAKING ABSTRACT: Fibroblast conditioned matrix: A new approach to study extracellular matrix (ECM) effects in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – Repair pathways: from lung development to ageing of the lung
Year: 2016
AAV-
Tgfb1
vs. bleomycin: Analysis of gene expression profiles in two models of pulmonary fibrosis
Source: International Congress 2014 – Novel approaches in transcriptomics and epigenomics in inflammatory lung diseases and lung cancer
Year: 2014
Idiopathic Pulmonary Fibrosis (IPF)
Source: ERS Course 2019 - Interstitial Lung Diseases
Year: 2019
Idiopathic Pulmonary Fibrosis (IPF)
Source: ERS Course 2019 - Interstitial Lung Diseases
Year: 2018
Idiopathic Pulmonary Fibrosis (IPF)
Source: ERS Courses: Interstitial Lung Diseases
Year: 2019
Elevated protein arginine methyltransferase 1 expression contributes to the pathogenesis of pulmonary fibrosis
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
IPFdatabase
– A new tool for a correct application of idiopathic pulmonary fibrosis guidelines
Source: International Congress 2014 – ILDs 2
Year: 2014
Identification of profibrotic cells in the Idiopathic Pulmonary Fibrosis (IPF) lung
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020
The myofibroblast in pulmonary fibrosis displays distinct functional characteristics, depending on its source of origin
Source: International Congress 2014 – ILDs 3
Year: 2014
Lipoxin (LXA
4
) as a novel therapy for idiopathic pulmonary fibrosis
Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases
Year: 2014
Surfactant protein B proforms as potential new biomarkers for idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 2
Year: 2014
Alveolar type II cells transplantation decrease fibrocyte migration in pulmonary fibrosis
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013
Proteasome function in lung fibrosis
Source: Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation
Year: 2013
Interstitial pulmonary fibrosis model develpment and identification of early biomarkers by MALDI imaging
Source: International Congress 2015 – New insights into IIPs
Year: 2015
Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis
Source: International Congress 2014 – ILDs 5
Year: 2014
MMP7-degraded elastin is elevated in serum of patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept